Kidney Transplantation Alone in End-Stage Renal Disease Patients With Hepatitis B Liver Cirrhosis: A Single-Center Experience

Background Kidney transplantation (KT) alone in end-stage renal disease (ESRD) patients with hepatitis B virus liver cirrhosis (LC) is controversial. This study compared outcomes of KT in hepatitis B surface antigen-positive patients with ESRD with (LC group) and without LC (non-LC group). Methods Outcomes were analyzed in103 hepatitis B surface antigen–positive patients with ESRD who underwent KT alone between 1997 and 2011. Ninety-one were in the non-LC group and 12 were in the LC group. Of the latter, eight were Child-Pugh (CP) class A and four were CP class B. Results Baseline aspartate transaminase and alanine transaminase levels were higher in the LC group. model for end-stage liver disease (MELD) scores were similar in patients with CP class A and class B, only serum albumin level was lower in CP class B. After KT, one CP class A patient showed an increase in the CP score from 5 to 10 points, MELD score from 22.3 to 44.1 points. The CP and MELD scores of the other 11 patients in the LC group did not increase. All four pre-KT CP class B patients were reclassified as class A after KT because of elevated serum albumin levels. Four patients in the LC group developed hepatocellular carcinoma at a median of 35 months (range, 20–57 months) after KT. The 5-year patient survival rate was similar in the LC and non-LC groups (100% vs. 94%, P=0.15). The incidence of pre-KT LC did not differ between survivors and nonsurvivors (11% vs. 18%, P=0.61). Occurrence of hepatocellular carcinoma was significantly higher in nonsurvivors than in survivors. Conclusion Kidney transplantation alone may be safe in patients with compensated hepatitis B virus LC.

[1]  Y. Kim,et al.  Evaluation of Nutrient Intake in Early Post Kidney Transplant Recipients , 2013, Clinical nutrition research.

[2]  J. Park,et al.  Long-term impact of prophylactic antiviral treatment in Hepatitis B surface antigen positive renal allograft recipients. , 2012, Clinical Nephrology.

[3]  D. Slakey,et al.  Kidney Transplantation Alone in ESRD Patients With Hepatitis C Cirrhosis , 2012, Transplantation.

[4]  D. Jin Current Status of Dialysis Therapy in Korea , 2011, The Korean journal of internal medicine.

[5]  D. Gerber,et al.  Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK) , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Ingsathit,et al.  Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. , 2007, Transplantation proceedings.

[7]  E. Furth,et al.  Effects of Hepatitis C-Induced Liver Fibrosis on Survival in Kidney Transplant Candidates , 2007, Digestive Diseases and Sciences.

[8]  C. Loong,et al.  Hepatocellular carcinoma after renal transplantation: the long-term impact of cirrhosis on chronic hepatitis B virus infection. , 2006, Transplantation proceedings.

[9]  T. Sauerbruch,et al.  Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[10]  M. Alter,et al.  Special Article: National Surveillance of Dialysis‐Associated Diseases in the United States, 2002 , 2005, Seminars in dialysis.

[11]  T. Chan,et al.  Preemptive lamivudine therapy based on HBV DNA level in HBsAg‐positive kidney allograft recipients , 2002, Hepatology.

[12]  Colin H. Jones,et al.  The relationship between serum albumin and hydration status in hemodialysis patients. , 2002, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[13]  M. Alter,et al.  National Surveillance of Dialysis‐Associated Diseases in the United States, 2000 , 2002, Seminars in dialysis.

[14]  W. Yang,et al.  RESULTS ON PREEMPTIVE OR PROPHYLACTIC TREATMENT OF LAMIVUDINE IN HBsAg (+) RENAL ALLOGRAFT RECIPIENTS: COMPARISON WITH SALVAGE TREATMENT AFTER HEPATIC DYSFUNCTION WITH HBV RECURRENCE , 2001, Transplantation.

[15]  L. Jeng,et al.  Hepatocellular carcinoma after kidney transplantation. , 1999, Transplantation proceedings.

[16]  P Coriat,et al.  Impact of hepatitis B and C virus on kidney transplantation outcome , 1999, Hepatology.

[17]  P. Coriat,et al.  Hepatic cirrhosis and kidney transplantation outcome. , 1997, Transplantation Proceedings.